Tesamorelin reached regulatory approval for HIV-associated abdominal fat on the strength of two phase 3 trials. We supply the compound, and the proof of what is in the vial.
Pooled result across two phase 3 trials versus placebo, measured by CT scan, with lean mass preserved.
Tesamorelin acts on the pituitary rather than replacing growth hormone, so natural pulsatility and feedback stay intact in the models studied.
The complete GHRH(1–44) sequence with a trans-3-hexenoyl group that shields it from DPP-4 breakdown and extends its half-life.
Figures describe published human clinical research on the compound. Apex Biohacks supplies {{ productName }} for in-vitro laboratory research only and makes no claims about its use.
Rather than supplying growth hormone, tesamorelin signals the body’s own axis. The published work follows that signal downstream.
Binds the GHRH receptor on somatotroph cells, the trigger for the body’s own growth-hormone pulse.
Pulsatile GH drives hepatic IGF-1, the marker the trials used to confirm the axis was engaged.
Downstream lipolysis in visceral fat is the endpoint measured by CT in the phase 3 programme.
{{ orderSub }}
Every lot goes to Brown Biology Lab, an ISO-17025-accredited, A2LA-certified independent facility, before it leaves our floor. The CoA in your box is the one anyone can pull from the public library.
Procurement-specific question? Email research@apexbiohacks.com — we typically reply the same business day.
All our products are for in-vitro research use only by qualified professionals. Not for human or animal use.
By entering, you confirm that you are a qualified researcher and accept our Terms, Privacy Policy, and Research Use Only Disclaimer.
We use essential cookies to run the site and, with your consent, analytics and marketing cookies to improve your experience. You can change your choice anytime. See our Privacy Policy.